Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 03.03.20
In Brazil, power sale contract with Braskem: Voltalia ready to build its biggest solar project - 270 megawatts  
In Brazil, power sale contract with Braskem: Voltalia ready to build its biggest solar project - 270 megawatts  
In Brazil, power sale contract with Braskem: Voltalia ready to build its biggest solar project - 270 megawatts  
eqs_en 
0 02.03.20
ALD closes sale of equity stake in ALD FORTUNE AUTO LEASING & RENTING in China
ALD closes sale of equity stake in ALD FORTUNE AUTO LEASING & RENTING in China
ALD closes sale of equity stake in ALD FORTUNE AUTO LEASING & RENTING in China
eqs_en 
0 28.02.20
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
DGAP-News: Abivax schließt ersten Patienten in US-amerikanische klinische Phase-1/2-Studie mit ABX196 zur Behandlung des Leberzellkarzinoms ein
eqs_de 
0 26.02.20
DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
DGAP-News: Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma
eqs_en 
0 26.02.20
Kaufman & Broad SA: AMENDMENT OF THE MANDATE FOR THE SHARE BUYBACK PROGRAM
Kaufman & Broad SA: AMENDMENT OF THE MANDATE FOR THE SHARE BUYBACK PROGRAM
Kaufman & Broad SA: AMENDMENT OF THE MANDATE FOR THE SHARE BUYBACK PROGRAM
eqs_en 
0 25.02.20
Voltalia acquires Greensolver and strengthens its services to third-party clients
Voltalia acquires Greensolver and strengthens its services to third-party clients
Voltalia acquires Greensolver and strengthens its services to third-party clients
eqs_en 
0 25.02.20
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
eqs_en 
0 18.02.20
ALD: ALD announces financial statements 2019
ALD: ALD announces financial statements 2019
ALD: ALD announces financial statements 2019
eqs_en 
0 13.02.20
RUBIS: Fourth quarter revenue up 12% - Volume growth and firm margins
RUBIS: Fourth quarter revenue up 12% - Volume growth and firm margins
RUBIS: Fourth quarter revenue up 12% - Volume growth and firm margins
eqs_en 
0 11.02.20
Voltalia SA: total number of shares and voting rights in the share capital as of January 31, 2020
Voltalia SA: total number of shares and voting rights in the share capital as of January 31, 2020
Voltalia SA: total number of shares and voting rights in the share capital as of January 31, 2020
eqs_en 
0 11.02.20
Voltalia SA: Smartenergy retains Voltalia to build and maintain solar farms in Portugal totaling 134 megawatts  
Voltalia SA: Smartenergy retains Voltalia to build and maintain solar farms in Portugal totaling 134 megawatts  
Voltalia SA: Smartenergy retains Voltalia to build and maintain solar farms in Portugal totaling 134 megawatts  
eqs_en 
0 10.02.20
RUBIS: Capital increase reserved for Group's employees
RUBIS: Capital increase reserved for Group's employees
RUBIS: Capital increase reserved for Group's employees
eqs_en 
0 07.02.20
ALD Q4 & FY 2019 results publication
ALD Q4 & FY 2019 results publication
ALD Q4 & FY 2019 results publication
eqs_en 
0 06.02.20
ALD reports full year 2019 results
ALD reports full year 2019 results
ALD reports full year 2019 results
eqs_en 
0 06.02.20
ALD announces management changes
ALD announces management changes
ALD announces management changes
eqs_en 
0 06.02.20
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.02.20
Kaufman & Broad SA: Sale-before-completion agreement for office space in Paris
Kaufman & Broad SA: Sale-before-completion agreement for office space in Paris
Kaufman & Broad SA: Sale-before-completion agreement for office space in Paris
eqs_en 
0 31.01.20
Kaufman & Broad SA: 2019 Annual Results
Kaufman & Broad SA: 2019 Annual Results
Kaufman & Broad SA: 2019 Annual Results
eqs_en 
0 30.01.20
DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien
DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien
DGAP-News: Abivax veranstaltet Satellite-Symposium auf dem 15. Kongress der 'European Crohn's and Colitis Organisation' (ECCO) in Wien
eqs_de 
0 28.01.20
DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna
DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna
DGAP-News: Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and Colitis Organization (ECCO) in Vienna
eqs_en 
0 28.01.20
Voltalia SA: half-year statement of the liquidity contract -as of December 31, 2019
Voltalia SA: half-year statement of the liquidity contract -as of December 31, 2019
Voltalia SA: half-year statement of the liquidity contract -as of December 31, 2019
eqs_en 
0 28.01.20
Voltalia SA: total number of shares and voting rights in the share capital as of December 31, 2019
Voltalia SA: total number of shares and voting rights in the share capital as of December 31, 2019
Voltalia SA: total number of shares and voting rights in the share capital as of December 31, 2019
eqs_en 
0 27.01.20
Voltalia SA: Highest quarterly revenues ever - Contracted future revenues climb over €5 billion
Voltalia SA: Highest quarterly revenues ever - Contracted future revenues climb over €5 billion
Voltalia SA: Highest quarterly revenues ever - Contracted future revenues climb over €5 billion
eqs_en 
0 22.01.20
Rubis to partner with I Squared Capital in Rubis Terminal
Rubis to partner with I Squared Capital in Rubis Terminal
Rubis to partner with I Squared Capital in Rubis Terminal
eqs_en 
0 21.01.20